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Abstract: Genome-wide association studies (GWAS) have identified immune-related genes as risk
factors for Alzheimer’s disease (AD), including TREM2 and CD33, frequently passing a stringent
false-discovery rate. These genes either encode or signal through immunomodulatory tyrosine-
phosphorylated inhibitory motifs (ITIMs) or activation motifs (ITAMs) and govern processes critical
to AD pathology, such as inflammation and amyloid phagocytosis. To investigate whether additional
ITIM and ITAM-containing family members may contribute to AD risk and be overlooked due to the
stringent multiple testing in GWAS, we combined protein quantitative trait loci (pQTL) data from
a recent plasma proteomics study with AD associations in a recent GWAS. We found that pQTLs
for genes encoding ITIM/ITAM family members were more frequently associated with AD than
those for non-ITIM/ITAM genes. Further testing of one family member, SIGLEC14 which encodes
an ITAM, uncovered substantial copy number variations, identified an SNP as a proxy for gene
deletion, and found that gene expression correlates significantly with gene deletion. We also found
that SIGLEC14 deletion increases the expression of SIGLEC5, an ITIM. We conclude that many genes
in this ITIM/ITAM family likely impact AD risk, and that complex genetics including copy number
variation, opposing function of encoded proteins, and coupled gene expression may mask these AD
risk associations at the genome-wide level.
Keywords: ITIM; ITAM; SIGLEC14; SIGLEC5; copy number variation; CNV; GWAS
1. Introduction
Genome-wide association studies (GWAS) have identified a set of polymorphisms that
modulate the risk of Alzheimer’s disease (AD) [1–6]. The pathways implicated in this pro-
cess include innate immunity, cholesterol homeostasis, and protein trafficking [7–9]. Four of
these genes, TREM2, CD33, PILRA, and FCER1G, are members of the family of non-catalytic
tyrosine-phosphorylated receptors (NTRs), which function through immunomodulatory
tyrosine-phosphorylated activating motifs (ITAMs) or inhibitory motifs (ITIMs). The un-
derlying immunomodulatory pathway is further implicated by AD-associated variants
in phospholipase C (PLCG2) and INPP5D which encode proteins acting downstream of
these ITAM- and ITIM-containing proteins. Functional studies have informed the cur-
rent hypothesis that the variants associated with AD in the ITAM/ITIM family modulate
inflammation and phagocytosis [10–18].
The ITAM family, including TREM2, recruit kinases such as spleen tyrosine kinase
(Syk) and phosphoinositide 3-kinase (PI3K) to induce downstream signaling, while the
ITIM family, including CD33, recruit phosphatases such as SHP-1 to dephosphorylate Syk
and ITAMs, thereby counteracting ITAM activity [19]. These ITAM and ITIM proteins
are predominantly expressed in immune cells such as microglia. Overall, these and other
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studies have shown that microglia contribute to AD pathogenesis, a concept that has been
reviewed recently [20–22].
The critical barrier to progress in translating GWAS candidate genes to treatments
is elucidating the actions of the functional variant at the molecular level, i.e., splicing
(sQTL), gene expression (eQTL), or protein level (pQTL), to understand whether the
pathway affected is detrimental or beneficial to disease risk. GWAS single nucleotide
polymorphisms (SNPs) in AD are frequently identified as eQTLs in the brain [23]. Sun et al.
have used GWAS to identify pQTLs for the plasma proteome, including ITIM and ITAM-
containing proteins [24]. To investigate the hypothesis that these pQTLs may uncover
additional AD-related genes that may have been overlooked in AD GWAS because of their
stringent false-discovery rate controls, we examined the Sun et al. cis-pQTL data together
with the Jansen et al. AD GWAS results. Parsing the proteins from the genome-wide
significant cis-pQTL dataset by whether or not an ITIM/ITAM domain was present, and
then examining whether the associated SNP is nominally significant (p < 0.05) for AD
association, found a significant overrepresentation of ITIM/ITAM encoding genes with
nominal AD associations. Since one of these genes, SIGLEC14, has been reported to be
deleted in some individuals, we investigated further and found that the pQTL and AD
SNP, rs1106476, is a proxy for the previously identified deletion polymorphism [25]. We
defined this deletion further by identifying additional SIGLEC14 copy number variants
and by determining the effect of SIGLEC14 copy number on the expression of SIGLEC14
and the neighboring SIGLEC5. We conclude that variants in ITIM/ITAM family members,
including SIGLEC14, represent underappreciated potential genetic risk factors for AD.
2. Materials and Methods
2.1. Preparation of gDNA, RNA, and cDNA from Human Tissue
Human blood and anterior cingulate autopsy tissue from 61 donors were generously
provided by the Sanders-Brown Alzheimer’s disease center neuropathology core and
have been described elsewhere [26]. The matched brain and blood samples were from
deceased individuals with an average age at death of 82.4 ± 8.7 (mean ± SD) years for
non-AD and 81.7 ± 6.2 years for AD subjects. The average postmortem interval (PMI) for
non-AD and AD subjects was 2.8 ± 0.8 and 3.4 ± 0.6 h, respectively. Non-AD and AD
samples were comprised of 48% and 55% female subjects. MMSE scores were, on average,
28.4 ± 1.6 for non-AD subjects and 11.9 ± 8.0 for AD subjects. These samples were used
for genotyping and gene expression studies. Three additional blood samples matched to
whole-genome sequencing (WGS) data were obtained to confirm WGS observations of
additional SIGLEC14 copies. DNA from these patients was prepared using a QIAamp DNA
Blood Mini kit (Qiagen, Germantown, MD, USA) per the manufacturer’s instructions.
2.2. Genotyping and Copy Number Variant Assays
Copy number variation in SIGLEC14 was determined using a TaqMan-based copy
number variant (CNV) assay (Invitrogen, Waltham, MA, USA; Catalog number 4400291,
Assay number Hs03319513_cn) compared to RNAse P (Invitrogen, 4403326). Amplifica-
tion and quantitation were performed per manufacturer instructions. Genotyping the
rs1106476 was performed with a custom TaqMan assay (Invitrogen). This assay discrimi-
nates rs1106476 and rs872629, which are in perfect LD. As coinherited SNPs, this variant is
also known as rs35495434.
2.3. Gene Expression by qPCR
Gene expression was quantified by qPCR with PerfeCTa SYBR Green master mix as pre-
viously described [14]. SIGLEC14 was quantified with primers corresponding to a sequence
in exons 3 and 5: 5′—CAGGTGAAACGCCAAGGAG—3′ and 5′—GCGAGGAACAGGGA
CTGG—3′. SIGLEC5 was quantified with primers corresponding to sequences in exons
4 and 5: 5′—ACCATCTTCAGGAACGGCAT—3′ and 5′—GGGAGCATCACAGAGCAGC—
3′. Cycling conditions for all qPCRs were as follows: 95 ◦C, 2 min; 95 ◦C, 15 s, 60 ◦C, 15 s,
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72 ◦C, 30 s, 40 cycles. Copy numbers present in the cDNA were determined relative to
standard curves that were executed in parallel [19].
2.4. WGS Data Analysis
To investigate the frequency and range of SIGLEC14 CNV, we performed a read-depth
analysis for WGS data. We obtained compressed sequence alignment map (CRAM) files
from the AD sequencing project (ADSP) and AD Neuroimaging (ADNI). We extracted
paired-end reads mapped to the SIGLEC14-SIGLEC5 locus under Genome Reference Con-
sortium Human Build 38 (GRCh38/hg38), and then computed the depth at each position
using the samtools depth function [27].
2.5. Statistical Analyses
The association of cis-pQTL proteins containing ITIM/ITAM domains and AD-associated
SNPs was calculated using a simple chi-square test. Gene expression was analyzed by using
JMP14 Pro using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc
multiple testing correction and graphed in GraphPad Prism 8.
3. Results
3.1. ITIM/ITAM pQTLs Are Overrepresented in AD GWAS Results
To evaluate whether pQTLs for ITIM or ITAM-containing proteins were associ-
ated with AD, we compiled a list of ITIM and ITAM-containing proteins from prior
reviews [28–31]. The resulting list contained 187 genes and is provided as Supplemental
Table S1. The cis-acting pQTLs from Sun et al. and AD associations from Jansen et al. were
then matched by chromosomal coordinates [2,24]. Both datasets were provided under
Genome Reference Consortium Human Build 37 (GRCh37/hg19). Genes were then subset
as either coding for an ITIM/ITAM gene or not and nominally significant (p < 0.05) for AD
association or not. The SNPs which are associated with both ITIM/ITAM protein levels
in plasma and AD risk are shown in Table 1. We found that pQTLs that affect ITIM or
ITAM genes were significantly overrepresented in nominally significant AD associations
(p = 6.51 × 10−5, χ21 = 15.95, Table 2).
Table 1. Genes that are nominally significant for AD association with strong pQTL signal.
Gene SNP P (pQTL) β(pQTL) P (AD) β (AD) N (AD)
ITIM/
ITAM
CD33 rs12459419 0 † −0.94 7.13 × 10−9 −0.01330 458,744 ITIM
FCGR3B rs10919543 3.20 × 10−67 0.44 0.000317 0.00806 445,293 ITAM
LILRA5 rs759819 2.50 × 10−111 −0.54 0.00186 0.00717 454,216 ITAM
LILRB2 rs373032 7.60 × 10−146 −0.72 0.00227 0.00763 463,880 ITIM
SIGLEC9 rs2075803 0 † −1.23 0.00703 0.00576 466,252 ITIM
SIRPB1 rs3848788 1.20 × 10−213 0.75 0.00942 0.00582 458,092 ITAM
COLEC12 rs2846667 9.30 × 10−12 0.20 0.0177 0.00586 449,987 ITAM
FCRL1 rs4971155 6.30 × 10−26 −0.26 0.0197 −0.00520 403,829 ITAM
NCR1 rs2278428 1.10 × 10−15 −0.36 0.0249 0.00815 466,252 ITAM
SIGLEC14 rs1106476 0 † −1.19 0.0284 0.00736 458,063 ITAM
FCRL3 rs7528684 1.40 × 10−112 0.53 0.04 −0.00434 458,744 Both
MRC2 rs146385050 1.30 × 10−11 −0.22 0.041 −0.00612 396,686 ITAM
SLAMF6 rs11291564 2.60 × 10−12 0.20 0.042 −0.02450 17,477 ITAM
† The p-value in the analyzed summary statistics was reported as exactly 0. This does not impact our analysis, as
our threshold was any cis-pQTL at p < 0.05.
Table 2. Overlap of pQTL and AD signals.
pQTLs ITIM/ITAM (%) Not ITIM/ITAM (%) Total
AD p < 0.05 13 (28) 54 (10) 67
AD p > 0.05 34 (72) 488 (90) 522
Total 47 (100) 542 (100) 589
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3.2. SIGLEC14 pQTL Is a Proxy for the Deletion Polymorphism
Previous reports have identified a SIGLEC14 deletion [25]. Given the strong pQTL
signal from rs1106476 on SIGLEC14 reported by Sun et al., and the fact that rs1106476 is
within the neighboring SIGLEC5 gene, yet has a cis-pQTL effect on SIGLEC14, we hypoth-
esized that rs1106476 is a proxy for the SIGLEC14 deletion polymorphism. To test this
hypothesis, we genotyped a set of DNA samples for rs1106476 and quantified genomic
copy number variation (CNV). We found that the proxy SNP correlates with SIGLEC14
deletion well but not perfectly (p < 0.0001, χ22 = 38.40) (Table 3). To better understand this
deletion, we then sequenced the region containing the SIGLEC14-SIGLEC5 fusion in five
minor allele carriers (two homozygous for SIGLEC14 deletion and three heterozygous) [25].
Based on these sequencing data, relative to reference sequences, we found a 692 bp region
of complete identity between SIGLEC14 and SIGLEC5. Within this region, the deletion
polymorphism sequence corresponds to SIGLEC14 at the 5′ end, but SIGLEC5 on the 3′ end,
with respect to reference sequence data (Figure 1). Overall, this represents a 17 kb deletion.
Table 3. Evaluation of rs1106476 as a proxy for SIGLEC14 deletion.
SIGLEC14 Copies rs1106476 T/T rs1106476 A/T rs1106476 A/A Total
0 0 1 1 2
1 6 13 0 19
2 39 0 0 39
3 2 2 0 4
Total 47 16 1 64
Blue = predicted correlation of SIGLEC14 deletion vs. rs1106476. Each cell represents the number of DNA samples
with the indicated SIGLEC14 copy number and rs1106476 genotype.




Figure 1. Identification of the SIGLEC14 deletion site. Coordinates in both are for reference genome. 
Exons 1-3 of SIGLEC14 and SIGLEC5 are identical which confounds exact determination of the cross-
over event. The yellow region depicts SIGLEC14, the blue region depicts SIGLEC5, while the green 
region depicts the 692 bp region of complete identity where the crossover deletion occurs. 
3.3. SIGLEC14 CNV Is Not Fully Captured by rs1106476 
As noted in Table 3, we found some individuals that had three copies of SIGLEC14 
as detected by the CNV assay. To validate these findings, we leveraged the ADNI and 
ADSP WGS datasets and compared read depth in the SIGLEC14 locus with surrounding 
sequences (Figure 2). Both datasets contained individuals with SIGLEC14 copy numbers 
ranging from 0–3. The presence of three copies of SIGLEC14 was cross-validated between 
WGS data and CNV assay in three individuals. Further, the frequencies across popula-
tions are equivalent (Table 4; p = 6.76 × 10−12, χ2 = 69.30). Read depths for Caucasian, African 
American, and other populations are shown as Supplemental Figures S1–S3. 
Figure 1. Identification of the SIGLEC14 deletion site. Coordinates in both are for reference genome.
Exons 1-3 of SIGLEC14 and SIGLEC5 are identical which confounds exact determination of the
crossover event. The yellow region depicts SIGLEC14, the blue region depicts SIGLEC5, while the
green region depicts the 692 bp region of complete identity where the crossover deletion occurs.
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3.3. SIGLEC14 CNV Is Not Fully Captured by rs1106476
As noted in Table 3, we found some individuals that had three copies of SIGLEC14
as detected by the CNV assay. To validate these findings, we leveraged the ADNI and
ADSP WGS datasets and compared read depth in the SIGLEC14 locus with surrounding
sequences (Figure 2). Both datasets contained individuals with SIGLEC14 copy numbers
ranging from 0–3. The presence of three copies of SIGLEC14 was cross-validated between
WGS data and CNV assay in three individuals. Further, the frequencies across populations
are equivalent (Table 4; p = 6.76 × 10−12, χ2 = 69.30). Read depths for Caucasian, African
American, and other populations are shown as Supplemental Figures S1–S3.




Figure 2. SIGLEC14 CNVs detected in ADNI and ADSP cohorts. Read depth shown by chromoso-
mal position of whole-genome sequencing in a representative example of each CNV detected. 
Exon/intron maps for SIGLEC14 and SIGLEC5 at figure top for reference. Purple: copy number var-
iation. Inset: expanded view of locus. Red dotted line: location of copy number variation assay. The 
dotted line in the insets shows the boundaries of the full-size image. 
Table 4. Summary of the SIGLEC14 CNV in the 3095 sample ADSP WGS dataset. 
SIGLEC14 Copy Number Caucasian African American Other Total 
0 24 74 44 142 
1 304 348 316 968 
2 692 522 652 1866 
3 21 53 43 117 
4 0 1 1 2 
Total 1041 998 1056 3095 
Deletion MAF 0.1691 0.2485 0.1913 0.2023 
Addition MAF 0.0101 0.0276 0.0213 0.0195 
MAF: Minor allele frequency 
Figure 2. SIGLEC14 CNVs detected in ADNI and ADSP coh rts. Read depth s own by chromosomal
position of whole-genome sequencing in a representative example of each CNV detected. Exon/intron
maps for SIGLEC14 and SIGLEC5 at figure top for reference. Purple: copy number variation. Inset:
expanded view of locus. Red dotted line: location of copy number variation assay. The dotted line in
the insets shows the boundaries of the full-size image.
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Table 4. Summary of the SIGLEC14 CNV in the 3095 sample ADSP WGS dataset.
SIGLEC14 Copy Number Caucasian African American Other Total
0 24 74 44 142
1 304 348 316 968
2 692 522 652 1866
3 21 53 43 117
4 0 1 1 2
Total 1041 998 1056 3095
Deletion MAF 0.1691 0.2485 0.1913 0.2023
Addition MAF 0.0101 0.0276 0.0213 0.0195
MAF: Minor allele frequency.
3.4. SIGLEC14 Is Expressed in Human Brain, and CNV Correlates with Gene Expression
To test whether gene expression compensation may neutralize the effect of genomic
SIGLEC14 deletion, we quantified SIGLEC14 expression relative to SIGLEC14 gene copy
number in cDNA prepared from human brain samples. Consistent with RNAseq studies
that show SIGLEC14 is expressed in microglia, SIGLEC14 expression strongly correlated
with expression of the microglial gene AIF1 (p < 0.0001, r2 = 0.409, Figure 3A) [19,32].
When SIGLEC14 expression is normalized to AIF1 expression, SIGLEC14 expression
was dependent in a step-wise manner with SIGLEC14 CNV (p = 0.0002, F2,47 = 10.679,
Figure 3B). Strikingly, individuals with one copy of SIGLEC14 have a mean SIGLEC14 ex-
pression of 54.6% compared to individuals with two copies. We interpret this to mean that
there is no compensatory increase in SIGLEC14 expression in individuals heterozygous for
SIGLEC14 deletion.
Figure 3. SIGLEC14 expression correlates with microglial gene AIF1 and SIGLEC14 CNV. (A)
SIGLEC14 is expressed in microglia (p < 0.0001, F1,48 = 33.19, r2 = 0.409). (B) SIGLEC14 CNV strongly
correlates with SIGLEC14 gene expression (p = 0.0002, F2,47 = 10.679), Tukey’s post-hoc multiple
comparisons test. ** p < 0.01. We do not have statistical power to compare expression with CNV > 2,
given its low MAF.
3.5. SIGLEC14 Deletion Leads to Increased SIGLEC5 Expression
To test whether SIGLEC5 expression changed with respect to SIGLEC14 deletion,
we quantified SIGLEC5 expression relative to SIGLEC14 CNV in these same brain sam-
ples. Since SIGLEC5 does not have its own promoter and there are no H3K27 acetylation
peaks between SIGLEC14 and SIGLEC5, we hypothesized that an inverse relationship
exists between SIGLEC14 CNV and SIGLEC5 expression, where a SIGLEC14 deletion
brings SIGLEC5 closer to the promoter leading to increased transcription (Supplemental
Figure S4) [33–35]. We found that SIGLEC5 expression significantly increases with respect
to SIGLEC14 genomic deletions (Figure 4; p = 0.0220, F2,46 = 4.151).
Genes 2021, 12, 1008 7 of 11




Figure 4. SIGLEC5 expression inversely correlates with SIGLEC14 CNV. SIGLEC5 expression in-
creases with fewer copies of SIGLEC14, presumably due to proximity to regulatory elements (p = 
0.0220, F2,46 = 4.151), Tukey’s post-hoc multiple comparisons test. * p = 0.0389. 
4. Discussion 
The primary finding of this paper is that pQTLs for ITIM and ITAM-containing pro-
teins are overrepresented as being nominally significant for AD risk, suggesting that the 
ITIM and ITAM family of proteins may contribute to AD pathogenesis. This adds to the 
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frequently identified genes predominantly expressed in microglia within the CNS as as-
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the ITIM/ITAM family of genes—which govern immune cell activation state—are more 
commonly associated with AD risk than variants for genes, not in this family (Table 2). 
Although we hypothesized that variants that enhanced ITAM levels or decreased ITIM 
levels would be associated with reduced AD risk, this was not observed. This likely indi-
cates that while some of these pQTLs may reflect increased functional signaling, others 
may involve alterations in splicing to generate soluble isoforms or may increase suscepti-
bility to cleavage from the cell surface. Hence, an SNP that associates with increased 
plasma protein levels does not necessarily correlate with increased cell surface expression 
and signaling. 
SIGLEC14 was selected for further investigation based on its previously reported de-
letion polymorphism and close relationship to another AD-associated gene, CD33 [2,25]. 
Since SNPs have previously been recognized as proxies for deletion of other genes [42–
44], and SIGLEC14 deletion has been previously reported [25], we hypothesized that the 
strong pQTL signal from rs1106476 reported in Sun et al. [24] correlated with SIGLEC14 
deletion. Indeed, we found that rs1106476 is a proxy for SIGLEC14 deletion and the minor 
allele count corresponds to the number of SIGLEC14 deletions in 89% of cases in our da-
taset (Table 3). 
This proxy variant does not, however, predict copy numbers greater than two. For 
instance, we observed four individuals with three copies of SIGLEC14; two of these indi-
viduals were homozygous minor for rs1106476 and two were heterozygous for rs1106476 
(Table 3). Additional copy number variation is also present in the ADSP and ADNI se-
quencing projects (Figure 2). These CNVs are equivalent across populations in these da-
tasets (Table 4, Supplemental Figures S1–S3). Based on these data and the recombination 
Figure 4. SIGLEC5 expression inversely correlates with SIGLEC14 CNV. SIGLEC5 expression increases
with fewer copies of SIGLEC14, presumably due to proximity to regulatory elements (p = 0.0220,
F2,46 = 4.151), Tukey’s post-hoc multi le co parisons test. * p = 0.0389.
4. Discussion
The primary finding of this paper is that pQTLs for ITIM and ITAM-containing
proteins are overrepresented as being nominally significant for AD risk, suggesting that
the ITIM and ITAM family of proteins may contribute to AD pathogenesis. This adds to
the current body of work which supports the hypothesis that AD is mediated, at least
in part, by immune cell dysfunction [1,4,5,36]. Indeed, transcriptomics and genomics
studies have frequently identified genes predominantly expressed in microglia within
the CNS as associated with AD risk [37–41]. Within a pQTL study, variants that affect
the expression of the ITIM/ITAM family of genes—which govern immune cell activation
state—are more commonly associated with AD risk than variants for genes, not in this
family (Table 2). Although we hypothesized that variants that enhanced ITAM levels or
decreased ITIM levels would be associated with reduced AD risk, this was not observed.
This likely indicates that while some of these pQTLs may reflect increased functional
signaling, others may involve alterations in splicing to generate soluble isoforms or may
increase susceptibility to cleavage from the cell surface. Hence, an SNP that associates with
increased plasma protein levels does not necessarily correlate with increased cell surface
expression and signaling.
SIGLEC14 was selected for further investigation based on its previously reported
deletion polymorphism and close relationship to another AD-associated gene, CD33 [2,25].
Since SNPs have previously been recognized as proxies for deletion of other genes [42–44],
and SIGLEC14 deletion has been previously reported [25], we hypothesized that the strong
pQTL signal from rs1106476 reported in Sun et al. [24] correlated with SIGLEC14 deletion.
Indeed, we found that rs1106476 is a proxy for SIGLEC14 deletion and the minor allele
count corresponds to the number of SIGLEC14 deletions in 89% of cases in our dataset
(Table 3).
This proxy variant does not, however, predict copy numbers greater than two. For
instance, we observed four individuals with three copies of SIGLEC14; two of these indi-
viduals were homozygous minor for rs1106476 and two were heterozygous for rs1106476
(Table 3). Additional copy number variation is also present in the ADSP and ADNI se-
quencing projects (Figure 2). These CNVs are equivalent acr ss populations in these
datasets (Table 4, Sup lemental Figures S1–S3). Based on these data and the recombination
peak which spans from upstr am of SIGLEC14 through ex n 8 f SIGLEC5 (Supplemental
Figure S5), we hypothesize that the additional copies integrate from a deletion event,
though far less frequently than the deletion itself [45]. Across the 3095 individual WGS
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dataset in ADSP, we found SIGLEC14 deletion has a minor allele frequency (MAF) of
0.2023, while insertion occurs at a MAF of only 0.0195, suggesting a 10-times lower rate of
integration than deletion (Table 4).
In the brain, SIGLEC14 is predominantly expressed in microglia, in keeping with
its putative role as an immune receptor (Figure 3A). The SIGLEC14 deletion polymor-
phism also strongly correlates with SIGLEC14 gene expression (Figure 3B). Due to the
low frequency of the additional copy integration, we do not have sufficient samples with
which to correlate SIGLEC14 expression to additional copy numbers, nor can we conclude
whether additional SIGLEC14 genomic copies are transcribed in frame and subsequently
produce protein.
We also find that SIGLEC14 deletion increases the expression of SIGLEC5 (Figure 4).
For individuals with at least one copy of SIGLEC14, the expression of SIGLEC14 is sub-
stantially higher than SIGLEC5. Coupled with the lack of an independent promoter or
H3K27 acetylation peaks between the two genes in GeneHancer or Encode, respectively,
we infer that expression of both genes is governed by a common promoter proximal to
SIGLEC14, that the integrity of this promoter is preserved after SIGLEC14 deletion, and that
SIGLEC14 deletion results in an increase in SIGLEC5 expression due to its closer proximity
to this common element. The SIGLEC family of receptors bind sialic acids as ligands to ini-
tiate their signaling cascades, and sialylated proteins, as well as gangliosides, are abundant
in amyloid plaques [46–48]. This decrease in expression of SIGLEC14, an ITAM-coupling
protein, and concomitant increase in expression of SIGLEC5, an ITIM-containing protein,
may lead to a dampened microglial activation state or proportion of activated microglia
in deletion carriers. We speculate that decreased SIGLEC14 expression and increased
SIGLEC5 expression may decrease the phagocytic capacity in AD. This is similar to the
inverse relationship between TREM2 and CD33, two well-known AD risk factors. Loss of
the ITAM-containing TREM2 decreases phagocytic capacity, while loss of CD33 increases
phagocytic capacity [11,13,49]. Since TREM2, which couples with DAP12, is critical for
the transition of microglia into a full disease-associated phenotype, SIGLEC14 may also
contribute to this transition [50]. Future studies could investigate whether at the single-cell
level SIGLEC14 CNV affects disease-associated microglial induction.
Copy number variation may represent a relatively unexplored source of genetic
variation in AD [51]. GWAS such as Jansen et al. rely on SNPs, which do not always
capture the full range of variation [2]. Additionally, “camouflaged” genes such as SIGLEC5
and SIGLEC14 with high sequence identity due to gene duplication are challenging for WGS
and WES technologies which rely on small fragments of DNA sequence, typically under
250 bp reads [51]. As such, variants which may have disease relevance and association
may be overlooked with current methods. SIGLEC14 is an example of one such possibly
overlooked risk contributor in AD. SIGLEC14 encodes an ITAM protein and signals through
DAP12 similar to TREM2, and deletion of SIGLEC14 is associated with increased AD risk,
also similar to SNPs that reduce TREM2 function [1,3–5]. Ligands for SIGLEC14, which
include sialylated proteins, are commonly found within amyloid plaques similar to ligands
for TREM2. We propose that the effect size and significance of association are masked
through copy number variation not accounted for using the proxy SNP alone, i.e., loss
of SIGLEC14 function likely increases risk, but the proxy SNP rs1106476 occasionally
also marks the individuals with an extra SIGLEC14 copy, thus reducing the power of
rs1106476 association with AD. We thus conclude that SIGLEC14 represents a potentially
overlooked AD genetic risk factor due to complex genetics.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/genes12071008/s1, Figure S1: Whole genome sequencing (WGS) read depth data from the
Alzheimer’s Disease Sequencing Project (ASDP) in Caucasian population, Figure S2: WGS read depth
data from the ASDP in African American population, Figure S3: WGS read depth data from the
ASDP in all other populations, Table S1: List of ITIM/ITAM genes and their aliases.
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